Horizon Therapeutics Public Limited Company
Symbol: HZNP
NASDAQ
116.3
USDTržní cena dnes
62.1155
Poměr P/E
0.5721
Poměr PEG
26.63B
MRK Cap
- 0.00%
Výnos DIV
Horizon Therapeutics Public Limited Company (HZNP) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 9289.14 | 2352.8 | 1580.3 | 2079.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.net-receivables | 2670.21 | 676.3 | 632.8 | 659.7 | |||||||||||||||
balance-sheet.row.inventory | 694.64 | 169.6 | 225.7 | 75.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 1549.86 | 449.3 | 360.9 | 255.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 14589.66 | 3652.8 | 2799.8 | 3070.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1376.4 | 340.5 | 292.3 | 189 | |||||||||||||||
balance-sheet.row.goodwill | 4042.15 | 1010.5 | 1066.7 | 413.7 | |||||||||||||||
balance-sheet.row.intangible-assets | 13725.2 | 3474.8 | 3840.1 | 1783 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 17767.35 | 4485.3 | 4906.8 | 2196.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 1842.66 | 431.8 | 538.1 | 560.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 858.6 | 204.1 | 140.7 | 55.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21845.01 | 5461.8 | 5878 | 3002.2 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.account-payables | 350.07 | 155.8 | 30.1 | 37.7 | |||||||||||||||
balance-sheet.row.short-term-debt | 64 | 16 | 16 | 0 | |||||||||||||||
balance-sheet.row.tax-payables | 172.07 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 10181.67 | 2546.8 | 2555.2 | 1003.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1263.5 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 3198.24 | 777.3 | 840.4 | 838 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12309.97 | 3093.3 | 3118.8 | 1171.5 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 15922.29 | 4042.4 | 4005.3 | 2047.3 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.09 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | 2612.75 | 590 | 318.6 | -215.9 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 48.28 | 12.5 | -15 | -0.1 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 17851.26 | 4469.6 | 4368.8 | 4241.4 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 36434.67 | - | - | - | |||||||||||||||
Total Investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.total-debt | 10245.67 | 2562.8 | 2571.2 | 1003.4 | |||||||||||||||
balance-sheet.row.net-debt | 986.05 | 210 | 990.9 | -1076.5 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 438 | 521.5 | 534.5 | 389.8 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 389 | 390.4 | 353.8 | 279.5 | |||||||||||||||
cash-flows.row.deferred-income-tax | -39.11 | 49.8 | -101 | -33.5 | |||||||||||||||
cash-flows.row.stock-based-compensation | 208.04 | 182.1 | 219.1 | 146.6 | |||||||||||||||
cash-flows.row.change-in-working-capital | -5.32 | -12 | -61.7 | -345.7 | |||||||||||||||
cash-flows.row.account-receivables | -44.08 | -43.5 | 34.8 | -251.2 | |||||||||||||||
cash-flows.row.inventory | 33.32 | 56.1 | 1.3 | -21.5 | |||||||||||||||
cash-flows.row.account-payables | 63.98 | 122.2 | -12.2 | 16 | |||||||||||||||
cash-flows.row.other-working-capital | -58.54 | -146.9 | -85.6 | -89.1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 50.03 | 126 | 90.7 | 118.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1040.64 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.acquisitions-net | 28.45 | -3.1 | -2845.3 | -262.3 | |||||||||||||||
cash-flows.row.purchases-of-investments | -8.57 | -9.2 | -24.7 | -13.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0.22 | 4.6 | -49.6 | -30 | |||||||||||||||
cash-flows.row.other-investing-activites | -28.45 | 0 | 51.6 | 41.4 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -142.87 | -134 | -2994.1 | -464.1 | |||||||||||||||
cash-flows.row.debt-repayment | -16 | -16 | -12 | -1.7 | |||||||||||||||
cash-flows.row.common-stock-issued | 34.99 | 30.3 | 0 | 919.8 | |||||||||||||||
cash-flows.row.common-stock-repurchased | -250.08 | -250.1 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | -103.35 | -112.2 | 1482.1 | -13.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -334.43 | -348 | 1470.1 | 904.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 8.77 | -2.5 | -10.6 | 7.2 | |||||||||||||||
cash-flows.row.net-change-in-cash | 572.11 | 773.4 | -499.3 | 1003.4 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 9278.67 | 2357.6 | 1584.2 | 2083.5 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 8706.56 | 1584.2 | 2083.5 | 1080 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1040.64 | 1257.8 | 1035.3 | 555.7 | |||||||||||||||
cash-flows.row.capital-expenditure | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.free-cash-flow | 906.13 | 1131.6 | 909.1 | 355.8 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3644.41 | 3629 | 3226.4 | 2200.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 903.44 | 920.2 | 794.5 | 532.7 | |||||||||||||||
income-statement-row.row.gross-profit | 2740.97 | 2708.8 | 2431.9 | 1667.7 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 515.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 770.1 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 2173.34 | 1979 | 1878.4 | 1182.6 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 3076.78 | 2899.2 | 2672.9 | 1715.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 441.47 | 497.2 | 365.9 | 278 | |||||||||||||||
income-statement-row.row.ebitda-caps | 957.03 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 513.37 | 617.4 | 543.1 | 490 | |||||||||||||||
income-statement-row.row.income-before-tax | 443.86 | 526.9 | 462.8 | 401.6 | |||||||||||||||
income-statement-row.row.income-tax-expense | 5.86 | 5.5 | -71.7 | 11.8 | |||||||||||||||
income-statement-row.row.net-income | 438 | 521.5 | 534.5 | 389.8 |
Často kladené otázky
Co je Horizon Therapeutics Public Limited Company (HZNP) celková aktiva?
Horizon Therapeutics Public Limited Company (HZNP) celková aktiva jsou 9114616000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 1777018000.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.752.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 3.873.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.120.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.141.
Co je Horizon Therapeutics Public Limited Company (HZNP) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 521482000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 2562837000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 1979014000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 2464623000.000.